MANE — Veradermics, Inc

NYSE · Health Care · Pharmaceuticals · CIK 1827635 ·
Last close
$102.50
Market Cap
$4.28B
52W High
$117.71
52W Low
$42.58
ADV30
648,116
Next earnings
Veradermics, Incorporated, a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was incorporated in 2019 and is headquartered in New Haven, Connecticut.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 0 -29,713,000 -27,232,000 397,356,000 168,412,000 6,716,000
Dec 2025 0 -22,753,000 -21,847,000 152,619,000 21,766,000 273,633,000
Sep 2025 18,797,000 5,660,000 114,812,000
Mar 2025 0 -12,882,000 -12,400,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-27,260,000
Investing CF
$-109,778,000
Financing CF
$199,818,000
CapEx
$-5,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.62
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-123,421,000
Inventory
Receivables
$1,255,000
ST Investments
$120,096,000
EBIT TTM
$-27,215,000
Pretax Income TTM
$-27,507,000
Interest Exp TTM
$292,000
Analysts
3

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 0 -71,557,000 -69,995,000 152,619,000 273,633,000 -71,602,000
Dec 2024 0 -26,384,000 -26,488,000 55,535,000 104,015,000 -23,688,000
Dec 2023 0 -17,324,000 -16,490,000 17,562,000 39,804,000 -13,510,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-3.00

Peers — same industry

TickerNameMarket CapLastDaily %
NAMS NewAmsterdam Pharma Co N.V. $4.22B $36.11
TVTX Travere Therapeutics, Inc. $4.12B $44.29
INDV Indivior Pharmaceuticals, Inc. $4.47B $37.81
GIKLY Grifols SA $4.48B $5.30
AMRX Amneal Pharmaceuticals, Inc. $4.08B $12.79

News headlines (Yahoo Finance, 1h cache)

Viking Stake In Veradermics Highlights Risky Growth And Ownership Shifts
2026-05-21 06:09 · Yahoo
Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026
2026-05-21 03:02 · Yahoo
The IPO Boom Isn’t in Tech and AI—Yet
2026-05-15 08:52 · Yahoo
Veradermics Announces Two Poster Presentations on VDPHL01 at the 2026 Music City SCALE Symposium
2026-05-14 11:30 · Yahoo
Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-05-12 11:30 · Yahoo
Citi Remains Bullish on Veradermics, Incorporated (MANE)
2026-05-10 23:12 · Yahoo
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill
2026-05-03 16:02 · Yahoo
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01
2026-04-30 13:57 · Yahoo
Veradermics Announces Pricing of Upsized Public Offering and Private Placement
2026-04-30 02:32 · Yahoo
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains
2026-04-29 09:46 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.